Back to Home

Neumora Therapeutics

NASDAQ: NMRA $1.51 USD ~$300M (post-Phase 3 selloff, June 2026) MCAP

Neumora Therapeutics is a clinical-stage neuroscience company developing precision medicines for brain diseases with high unmet need. Its lead asset NMRA-140 (navacaprant) is a kappa opioid receptor antagonist studied in major depressive disorder, and the company has additional programs in schizophrenia and other CNS indications. Following two Phase 3 failures in mid-2026, Neumora announced a 35% workforce reduction and is discontinuing development of its lead depression asset.

Company Info

Sector: Biotechnology / Neuroscience (Precision Psychiatry)
Headquarters: Watertown, Massachusetts, USA
Founded: 2019

Upcoming Milestones & Key Dates

Q3 2026
Corporate

Completion of 35% workforce reduction and pipeline restructuring

Late 2026
Corporate

Strategic review of remaining pipeline and cash runway guidance

Clinical Development Pipeline

NMRA-140 (navacaprant)

Target: Kappa opioid receptor (KOR) antagonist
Major Depressive Disorder
Preclinical
Phase 1
Phase 2
Phase 3
Approved

NMRA-140 (navacaprant)

Target: Kappa opioid receptor (KOR) antagonist
Adjunctive treatment of MDD with anhedonia
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Preclinical KOR / DOR programs

Target: Opioid receptor modulators
Mood and anxiety disorders
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Henry Gosebruch

President and Chief Executive Officer

To be confirmed

Chief Medical Officer

To be confirmed

Chief Scientific Officer

Careers & Job Openings

See all open roles

Multiple Departments
See careers page
Apply Now